Company profilePrivate / Non-listed

NanoAlvand Company

NanoAlvand Pharmaceutical Company is a private Iranian knowledge-based pharmaceutical manufacturer founded in 2011. It develops and produces highly potent medicines from a Karaj manufacturing site, with a Tehran head office, serving oncology and other specialist therapeutic areas. The company matters to buyers, suppliers and investors focused on localized specialty-drug production and complex dosage-form capability in Iran.

ListingPrivate / Non-listed
ExportMedium
VerificationBasic
ConfidenceHigh
Updated20/07/2026
Market Role

Market position

NanoAlvand operates in Iran’s specialty and high-potency pharmaceutical segment, focusing on medicines for oncology and other complex therapeutic indications.

OPERATING PROFILE

Operations & footprint

Products and services

NanoAlvand Company develops and manufactures high-potency and specialized pharmaceutical products, with product fields including oncology, neurology, rheumatology, and other advanced therapeutic categories. Its activity is linked to complex generics, hazardous drug manufacturing, sterile or controlled production environments, regulatory documentation, clinical access, import substitution, and high-value pharmaceutical technology.

Operations and assets

The company operates production lines for high-risk pharmaceutical products at its Karaj site. Manufacturing formats include injectable vials, tablets, capsules and pre-filled syringes.

Geographic footprint

Iranian operations span a Tehran head office and a manufacturing site in Karaj, Alborz Province.

CORPORATE STRUCTURE

Ownership & group structure

Ownership

Knowledge-based company.

Investor Lens

Commercial and investment relevance

NanoAlvand is relevant for investors assessing Iran's advanced pharmaceutical manufacturing, oncology and specialty-drug demand, high-potency production capability, import substitution, technology gaps, and export potential in complex generics. It can support analysis of how local firms move from basic generics toward higher-value medicines under regulatory and sanctions constraints. Due diligence should verify ownership, GMP status, product registrations, current manufacturing sites, active pharmaceutical ingredient sourcing, export registrations, pharmacovigilance systems, intellectual-property exposure, quality-control capacity, and international market access. The company is relevant to buyers and healthcare distributors seeking Iranian-made specialty medicines, and to suppliers of active pharmaceutical ingredients, sterile-manufacturing inputs, packaging and quality systems for high-potency products.

DECISION RISKS

Constraints, risk & compliance

Key risks and constraints

Its focus on high-potency and specialist medicines raises requirements for controlled manufacturing, product quality, pharmacovigilance and reliable access to pharmaceutical inputs. Commercial performance is closely tied to product registration and supply continuity in specialist therapeutic categories.

LOCAL COMPANY ACCESS

Need more than a public profile?

Ask Hormuz to investigate, verify or act locally around NanoAlvand Company. Tell us exactly what you need.

Contact the companyVerify local presenceArrange a site visitRequest pricingCheck capacitySpeak with salesConfirm specific informationCover an exhibition
Open a Desk request No service is preselected.
Related context

Connected Intelligence

Relevant geography, industry, market and execution context for this profile.

Common questions

Frequently asked questions

Direct answers to the questions most likely to arise when reviewing this profile.

What does NanoAlvand Pharmaceutical Company manufacture?

NanoAlvand manufactures highly potent pharmaceutical products in injectable-vial, tablet, capsule and pre-filled-syringe formats for oncology and other specialist therapeutic areas.

Where does NanoAlvand operate?

The company has a head office in Tehran and a manufacturing site in the Simindasht Industrial Area of Karaj, Alborz Province, Iran.

When was NanoAlvand founded?

NanoAlvand Pharmaceutical Company was founded in 2011.

Which therapeutic areas does NanoAlvand serve?

Its portfolio includes oncology, neurology, rheumatology, multiple sclerosis, fungal infections, organ transplant rejection prevention, osteoporosis, pulmonary hypertension, COVID-19 and autoimmune diseases.